Mark Morgan's Lab

Receptor Dynamics in Cancer Laboratory / Institute of Systems, Molecular & Systems Biology / University of Liverpool, UK

[Mark Morgan's Lab @M_MorganLab]

Very excited to share our latest paper describing crosstalk between αvβ6 integrin & HER2 in breast cancer invasion & drug resistance.
Great work by @HJMald & many others
https://t.co/PdTG1XsPZE
@ScienceAdvances @LivUniISMIB @AdamHurlstone Many thanks to @BCCare @NorthWestCancer

[Inst of Systems, Molecular & Integrative Biology @LivUniISMIB]

NEWS | New insights in breast cancer progression and drug resistance

➡️ https://t.co/c8mp9fx2kx

#CancerResearch | #TeamLivUni

[Ben Goult @bengoult]

Look at the amazing speaker list for Adhere2 next September!
This is going to be an excellent meeting, in beautiful Zadar, Croatia.

https://t.co/o6u0LywicO

[Mark Morgan's Lab @M_MorganLab]

@TomVanAgtmael @RobinsonLab_QIB @HJMald @ScienceAdvances @LivUniISMIB @AdamHurlstone @BCCare @NorthWestCancer Thanks Tom. We’re really pleased with the paper. Although, as always, it raises many more questions…

[Mark Morgan's Lab @M_MorganLab]

Very excited to share our latest paper describing crosstalk between αvβ6 integrin & HER2 in breast cancer invasion & drug resistance.
Great work by @HJMald & many others
https://t.co/PdTG1XsPZE
@ScienceAdvances @LivUniISMIB @AdamHurlstone Many thanks to @BCCare @NorthWestCancer

[Mark Morgan's Lab @M_MorganLab]

6) High levels of GDI2 expression correlate with better patient survival

7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

[Mark Morgan's Lab @M_MorganLab]

6) High levels of GDI2 expression correlate with better patient survival

7) Levels of αVβ6 expression at initial diagnosis predict disease relapse following trastuzumab treatment

[Mark Morgan's Lab @M_MorganLab]

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

[Mark Morgan's Lab @M_MorganLab]

A particularly intriguing observation: Invasion of trastuzumab resistant cells is αVβ6-independent. But resistant cells express very high levels αVβ6 on the cell surface. Opening up opportunities to potentially target them with an αVβ6-targeting warhead, or immuno-modulator

[Mark Morgan's Lab @M_MorganLab]

5) Components of the trafficking regulatory subnetwork are highly expressed in HER2+ breast cancers expressing high levels of αVβ6.

[Mark Morgan's Lab @M_MorganLab]

4) RAB5, RAB7A, and GDI2 differentially regulate invasion and αVβ6 integrin-mediated TGFβ activation, but this mechanism is uncoupled by trastuzumab resistance, rendering cells unresponsive to αVβ6, HER2 or TGFβ-Receptor inhibition.

[Mark Morgan's Lab @M_MorganLab]

2) Components of the trafficking regulatory subnetwork mediate direct crosstalk between αVβ6 and HER2, affecting receptor trafficking and signalling.

3) Trastuzumab resistance disrupts αVβ6-mediated control of HER2 endocytosis and signalling.

[Mark Morgan's Lab @M_MorganLab]

We show that:
1) Integrin αVβ6 recruits HER2 and a RAB5/RAB7A/GDI2 trafficking regulatory subnetwork. This recruitment is enhanced by exposure to the HER2-trageting drug trastuzumab, but dysregulated following acquired trastuzumab resistance.

[Ben Goult @bengoult]

Very excited to share our new paper on Talin binding to Amyloid Precursor Protein indicating a new way to think about Alzheimer's Disease.

It has the most provocative discussion section we have ever written :)

https://t.co/MfJtvQ91Db

[Horacio Maldonado @HJMald]

Excited to share that our latest paper on the crosstalk between integrin αVβ6 and HER2 in HER2+ breast cancer is OUT!
@M_MorganLab @LivUniCancer @ScienceAdvances @LivUniISMIB #BreastCancer #Trastuzumab

https://t.co/3GuMge62mP

[LCRI @LivCancerRes]

Great to meet you face to face for the first time @M_MorganLab & thank you for a great talk @LivCancerRes #LCR121! So much opportunity for #collaboration in tumour micro-environment and #immuno-oncology studies across @LivUniISMIB @livuniHLS @livuninews @LivHPartners